

## Surveillance proposal consultation document

### 2023 surveillance of Myeloma (NICE NG35)

The myeloma guideline has a section on preventing infection ([section 1.8](#)) but does not currently recommend prophylactic antibiotics (or advise against them) for patients with newly diagnosed myeloma who are starting therapy. This is because the evidence was too weak to develop recommendations at the time of guideline development in 2016.

The current exceptional review looks at the impact of the publication of the [TEAMM trial](#) (2019) and the [meta-analysis on antibiotic prophylaxis for patients with newly diagnosed multiple myeloma](#) (2019) on [section 1.8](#) of the [Myeloma guideline](#) (NICE guideline NG35).

The consultation includes the following questions:

1. Do you agree with the proposal not to update the section 1.8 of guideline on Myeloma (NICE guideline NG35)?

Please could let us know if you agree or disagree (yes/no) and if you disagree can you provide your comments or rationales?

2. Are you aware of any additional randomised controlled trials (RCTs) (published or ongoing trials) on this topic area?

3. Are you aware of any health inequality issues in this area? If yes, can you provide your comments?

4. What is the current practice in your centre/local area? Do you routinely provide antibiotic prophylaxis for people with newly diagnosed myeloma who are starting therapy?

**Please note:** Responses to consultation questions will need to be submitted online, by signing into your NICE account. The consultation closes at **5pm on Friday 12th May 2023**.